Home / Health / FDA OKs New Dwarfism Therapy for Kids
FDA OKs New Dwarfism Therapy for Kids
28 Feb
Summary
- U.S. FDA approved Ascendis Pharma's new therapy.
- The treatment is for children with rare dwarfism.
- This medication is administered once weekly.
The U.S. Food and Drug Administration has granted approval for Ascendis Pharma's innovative therapy designed for children diagnosed with a rare genetic disorder leading to dwarfism. This significant development was announced by the company.
The newly approved treatment offers a once-weekly dosage regimen. This addresses a critical need for accessible and manageable treatment options for pediatric patients facing this complex genetic condition.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
